Hormone Research in Paediatrics
Case Report
Increased MIB-1/Ki-67 Labeling Index as a Predictor of an Aggressive Course in a Case of ProlactinomaZornitzki T.a · Knobler H.a · Nass D.b · Hadani M.c · Shimon I.daDivision of Endocrinology, Kaplan Medical Center, Hebrew University and Hadassah School of Medicine, Jerusalem, and bInstitute of Pathology, cDepartment of Neurosurgery, and dInstitute of Endocrinology, Sheba Medical Center, Tel Hashomer, Israel
|
|
Horm Res 2004;61:111–116
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Received: May 26, 2003
Accepted: October 05, 2003
Published online: March 17, 2004
Issue release date: March 2004
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Abstract
Secondary resistance to dopamine agonists is a rare phenomenon in patients with a prolactinoma. We describe a 55-year-old male with a macroprolactinoma initially responding favorably to bromocriptine treatment with normalization of prolactin levels and tumor shrinkage. Two years later, he developed resistance to bromocriptine treatment and subsequently to cabergoline. The aggressive course of the disease necessitated three surgical interventions. Staining of the pituitary tissue revealed a very high MIB/Ki-67 labeling index that increased further in specimens derived from repeated surgery. This case demonstrates that high and increasing levels of the MIB/Ki-67 labeling index may indicate an aggressive course associated with secondary dopamine resistance.
© 2004 S. Karger AG, Basel
Related Articles:
References
- Molith ME: Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28:143–169.
- Colao A, DiSarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574–3579.
- Colao A, DiSarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2247–2252.
- Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A: Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84:2518–2522.
- Colao A, DiSarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G: Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876–883.
- Delgrande E, Maiter D, Donckier J: Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454–456.
- Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A: Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500–509.
- Brue T, Pellegrini I, Priou A, Morange I, Jaquet P: Prolactinomas and resistance to dopamine agonists. Horm Res 1992;38:84–89.
- Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A, Jaquet P: Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74:577–584.
- Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Becker W: Prolactin-producing pituitary tumor: Resistance to dopamine agonist therapy. J Neurosurg 1995;82:886–890.
- Delgrande E, Crabbe J, Donckier J: Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 1998;49:250–253.
- Schwarzstein D, Garcia-Patterson A, Gimenez G, Calaf J, Puig-Domingo M, Caixas A, Matias-Guiu X, Webb SM: Dopaminergic resistance in a case of invasive macroprolactinoma. J Endocrinol Invest 1993;16:443–447.
- Pernicione PJ, Scheithauer BW, Sebo TJ, Kovacs K, Norvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC: Pituitary carcinoma: A clinicopathologic study of 15 cases. Cancer 1997;79:804–812.
- Jaffrain Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G: A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumors: Secreting versus non-secreting adenomas. Endocr Relat Cancer 2002;9:103–113.
-
Thapar K, Yamada Y, Scheithauer B, Kovacs K, Stefaneanu L: Assessment of mitotic activity in pituitary adenomas and carcinomas. Endocr Pathol Update 1996;7:215–221.
- Thapar K, Kovacs K, Scheithauer B, Stefaneanu L, Horvath E, Pernicione PJ, Murray D, Laws ER Jr: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody. Neurosurgery 1996;38:99–106.
- Ma W, Ikeda H, Yoshimoto T: Clinicopathologic study of 123 cases of prolactin secreting pituitary adenomas with special reference to multihormone production and clonality. Cancer 2002;95:258–266.
- Turner HE, Wass JA: Are markers of proliferation valuable in the histological assessment of pituitary tumors? Pituitary 1999;1:147–151.
- Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A: The natural history of untreated hyperprolactinemia: A prospective analysis. J Clin Endocrinol Metab 1989;68:412–418.
- Weiss MH, Teal J, Gott P, Wycoff R, Yardley R, Apuzzo ML, Giannota SL, Kletzky O, March C: Natural history of microprolactinomas: Six-year follow-up. Neurosurgery 1983;12:180–183.
- Yokoyama S, Hirano H, Moroki K, Goto M, Imamura S, Kuratsu JI: Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery 2001;49:857–862.
- Espay AJ, Azzarelli B, Williams LS, Bodensteiner JB: Recurrence in pituitary adenomas in childhood and adolescence. J Child Neurol 2001;16:364–367.
- Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M: Proliferation index of nonfunctioning pituitary adenomas: Correlations with clinical characteristics and long-term follow-up results. Neurosurgery 2000;47:1313–1318.
- Losa M, Barzaghi R, Mortini P, Franzin A, Mangili F, Terreni MR, Giovanelli M: Determination of the proliferation index in adrenocorticotropin-secreting pituitary tumors: Comparison between micro- and macroadenomas. Am J Pathol 2000;156:245–251.
- Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Ruggeri A, Peciarolo A: Adrenocorticotropic hormone secreting pituitary adenomas: Analysis of growth fraction using the MIB-1 antibody. Tumori 2000;86:229–232.
- Delgrange E, Trouillas J, Maiter D, Donckier J,Tourniaire J: Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J Clin Endocrinol Metab 1997;82:2102–2107.
- Calle-Rodrigue R, Giannini C, Scheithauer B, Lloyd R, Wollan P, Kovacs K, Stefaneanu L, Ebright A, Abboud C, Davis D: Prolactinomas in male and female patients: A comparative clinicopathologic study. Mayo Clin Proc 1998;73:1046–1052.
Article / Publication Details
First-Page Preview
Received: May 26, 2003
Accepted: October 05, 2003
Published online: March 17, 2004
Issue release date: March 2004
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 0
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
